vs
Side-by-side financial comparison of Lakeshore Acquisition III Corp. (LCCC) and Scinai Immunotherapeutics Ltd. (SCNI). Click either name above to swap in a different company.
Scinai Immunotherapeutics Ltd. is the larger business by last-quarter revenue ($773.0K vs $717.3K, roughly 1.1× Lakeshore Acquisition III Corp.).
LCCC vs SCNI — Head-to-Head
Income Statement — Q3 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $717.3K | $773.0K |
| Net Profit | $486.8K | — |
| Gross Margin | — | — |
| Operating Margin | -32.1% | — |
| Net Margin | 67.9% | — |
| Revenue YoY | — | 172.2% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.08 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $717.3K | — | ||
| Q2 25 | $467.3K | $773.0K | ||
| Q2 24 | — | $284.0K |
| Q3 25 | $486.8K | — | ||
| Q2 25 | $216.5K | — | ||
| Q2 24 | — | — |
| Q3 25 | -32.1% | — | ||
| Q2 25 | -53.7% | — | ||
| Q2 24 | — | — |
| Q3 25 | 67.9% | — | ||
| Q2 25 | 46.3% | — | ||
| Q2 24 | — | — |
| Q3 25 | $0.08 | — | ||
| Q2 25 | $0.06 | — | ||
| Q2 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $989.0K |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-1.6M | $7.9M |
| Total Assets | $71.0M | $11.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | — | ||
| Q2 25 | — | $989.0K | ||
| Q2 24 | — | $3.1M |
| Q3 25 | $-1.6M | — | ||
| Q2 25 | $-1.4M | $7.9M | ||
| Q2 24 | — | $-7.3M |
| Q3 25 | $71.0M | — | ||
| Q2 25 | $70.5M | $11.8M | ||
| Q2 24 | — | $14.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-206.3K | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | -0.42× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-206.3K | — | ||
| Q2 25 | $-218.3K | — | ||
| Q2 24 | — | — |
| Q3 25 | -0.42× | — | ||
| Q2 25 | -1.01× | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
